Subscribe to RSS

DOI: 10.1055/a-2773-5644
Prognostic Value of BARC-defined Bleeding in East Asian Acute Myocardial Infarction Patients: Evidence from Multicentre Registries in Korea and Japan
Authors
Funding Information This work was supported in part by the First Incentive Payment for Medical Technology and research from the Naohiko Miyata-Asahi Intecc Foundation for Medical Technology. The JAMIR was planned by the Japan Cardiovascular Research Foundation and funded by Daiichi Sankyo Co., Ltd. KAMIR was funded by the Research Program of Korea Centers for Disease Control and Prevention (2016-EER6304–02).

Abstract
Background
The Bleeding Academic Research Consortium (BARC) classification was proposed to standardize bleeding endpoint definitions and reports in cardiovascular clinical trials. However, its prognostic value has not been fully validated in East Asian patients with acute myocardial infarction (AMI) who have a higher bleeding risk than Western populations do.
Methods
We analyzed bleeding events (types 2 or 3) based on the BARC classification in 13,657 patients with AMI (mean age 64.9 ± 12.7 years) from nationwide prospective registries in Japan and Korea. The primary endpoint was all-cause mortality during the 1-year clinical follow-up.
Results
During the 1-year follow-up, BARC type 2 or 3 bleeding occurred in 5.5% of the patients (n = 759). Patients who experienced BARC type 2 or 3 bleeding had a significantly higher risk of mortality compared with those without bleeding (hazard ratio [HR] 4.1, 95% confidence interval [CI] 3.4–4.8, p < 0.001). The risk of mortality was higher in BARC type 3 (HR 6.4, 95% CI 5.1–7.9) than in type 2 bleeding (HR 2.4, 95% CI 1.8–3.1). BARC type 2 or 3 bleeding remained significantly associated with increased mortality after adjustment (adjusted HR 1.9, 95% CI 1.5–2.5, p < 0.001). Similar associations with mortality were observed when each BARC classification (type 2 and 3) was analyzed individually.
Conclusion
In East Asian patients with AMI, BARC-defined bleeding events were significantly associated with increased mortality. These findings support the adoption of the BARC classification to predict mortality, particularly in East Asian patients with AMI.
Data Availability Statement
The deidentified participant data will not be shared.
‡ These authors contributed equally to this work.
Publication History
Received: 09 May 2025
Accepted after revision: 15 December 2025
Article published online:
06 January 2026
© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48 (07) 1319-1325
- 2 D'Ascenzo F, Bertaina M, Fioravanti F. et al. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: insights from the RENAMI registry. Eur J Prev Cardiol 2020; 27 (07) 696-705
- 3 Hochholzer W, Wiviott SD, Antman EM. et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011; 123 (23) 2681-2689
- 4 Kazi DS, Leong TK, Chang TI, Solomon MD, Hlatky MA, Go AS. Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. J Am Coll Cardiol 2015; 65 (14) 1411-1420
- 5 Baber U, Dangas G, Chandrasekhar J. et al. Time-dependent associations between actionable bleeding, coronary thrombotic events, and mortality following percutaneous coronary intervention: results from the PARIS Registry. JACC Cardiovasc Interv 2016; 9 (13) 1349-1357
- 6 Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007; 154 (01) 3-11
- 7 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
- 8 Vranckx P, White HD, Huang Z. et al. Validation of BARC bleeding criteria in patients with acute coronary syndromes: the TRACER trial. J Am Coll Cardiol 2016; 67 (18) 2135-2144
- 9 Ndrepepa G, Schuster T, Hadamitzky M. et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125 (11) 1424-1431
- 10 Vranckx P, Leonardi S, Tebaldi M. et al. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. Eur Heart J 2014; 35 (37) 2524-2529
- 11 Tarantini G, Honton B, Paradies V. et al; TARGET-FIRST Investigators. Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction. N Engl J Med 2025; 393 (21) 2083-2094
- 12 Schüpke S, Neumann FJ, Menichelli M. et al; ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019; 381 (16) 1524-1534
- 13 Hong SJ, Lee SJ, Suh Y. et al; T-PASS (Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome) Investigators. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation 2024; 149 (08) 562-573
- 14 Natsuaki M, Watanabe H, Morimoto T. et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation 2024; 149 (08) 585-600
- 15 Kwon O, Park DW. Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations. JACC Asia 2022; 2 (01) 1-18
- 16 Honda S, Nishihira K, Kojima S. et al; JAMIR investigators. Rationale, design, and baseline characteristics of the prospective Japan Acute Myocardial Infarction Registry (JAMIR). Cardiovasc Drugs Ther 2019; 33 (01) 97-103
- 17 Yasuda S, Honda S, Takegami M. et al; JAMIR Investigators. Contemporary antiplatelet therapy and clinical outcomes of Japanese patients with acute myocardial infarction—results from the prospective Japan Acute Myocardial Infarction Registry (JAMIR). Circ J 2019; 83 (08) 1633-1643
- 18 Thygesen K, Alpert JS, Jaffe AS. et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation 2012; 126 (16) 2020-2035
- 19 Oh S, Jeong MH, Cho KH. et al. Outcomes of nonagenarians with acute myocardial infarction with or without coronary intervention. J Clin Med 2022; 11 (06) 1593
- 20 Rao SV, O'Donoghue ML, Ruel M. et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2025; 151 (13) e771-e862
- 21 Hara H, Takahashi K, Kogame N. et al. Impact of bleeding and myocardial infarction on mortality in all-comer patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2020; 13 (09) e009177
- 22 Tung YC, See LC, Chang SH, Liu JR, Kuo CT, Chang CJ. Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease. Sci Rep 2020; 10 (01) 21345
- 23 Lattuca B, Cayla G, Silvain J. et al; ACTION Study Group. Bleeding in the elderly: risk factors and impact on clinical outcomes after an acute coronary syndrome, a sub-study of the randomized ANTARCTIC trial. Am J Cardiovasc Drugs 2021; 21 (06) 681-691
- 24 Gragnano F, van Klaveren D, Heg D. et al. Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention. Circulation 2025; 151 (06) 343-355
- 25 Urban P, Mehran R, Colleran R. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019; 40 (31) 2632-2653
- 26 Freund A, Jobs A, Lurz P. et al. Frequency and impact of bleeding on outcome in patients with cardiogenic shock. JACC Cardiovasc Interv 2020; 13 (10) 1182-1193